Prokinecitine in Acute Myocardial Infarction (Prok-Idm)

August 19, 2019 updated by: University Hospital, Strasbourg, France

Pilot Study Prok-Idm: Interest of Dosage of Prokinecitine in Acute Myocardial Infarction

The study aims to investigate the presence of a substance in the blood called prokinecitine, which is released by the heart when a heart attack occurs. Several venous blood samples at the arm are withdrawn at admission, H6, H12, H24, H48 and H72 in order to measure the concentration of this substance in the blood. The usefulness of this new blood marker is going to be determsined to seek if it would be of help to better diagnose or estimate the gravity of heart infarction after a heart attack.

Study Overview

Status

Terminated

Conditions

ST Elevatation Myocardial Infarction (STEMI)

Study Type

Observational

Enrollment (Actual)

172

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

France
- - Strasbourg, France, 67000
    - University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with acute St elevation myocardial infarction of less than 6 hours

Description

Inclusion Criteria:

Patients with acute St elevation myocardial infarction of less than 6 hours
Age>18 y/o

Exclusion Criteria:

Previous myocardial infarction
LBB, RBB
Renal Insuffiency MDRD<30 mL/min
Patient with Pace-Maker or ICD.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Infarct size by MRI necrotic myocardial mass Time Frame: 7 days	Infarct size by MRI necrotic myocardial mass	7 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Strasbourg, France

Investigators

Principal Investigator: Patrick OHLMANN, MD, University Hospital, Strasbourg, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2013

Primary Completion (Actual)

February 1, 2019

Study Completion (Actual)

February 1, 2019

Study Registration Dates

First Submitted

December 19, 2013

First Submitted That Met QC Criteria